Risk factors of recurrence in TNM stage I colorectal cancer

Paik, Jin-Hee; Ryu, Chun-Geun; Hwang, Dae–Yong

doi:10.4174/astr.2023.104.5.281

Cited by 8 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The choice of adjuvant chemotherapy is based on the risk of recurrence, which usually depends on pathological tumor staging [4,5]. The recurrence rate is 3-5% in stage I CRC patients, 10-17% in stage II CRC patients and 31-40% in stage III CRC patients during follow-up [14,15]. Moreover, stage III CRC patients experience disease relapse sooner than the early-stage patients.…”

Section: Prevention and Detection Of Colorectal Cancer Recurrencementioning

confidence: 99%

Current Applications and Future Directions of Circulating Tumor Cells in Colorectal Cancer Recurrence

Tsai,

Huang,

Chu

et al. 2024

Cancers

View full text Add to dashboard Cite

The ability to predict or detect colorectal cancer (CRC) recurrence early after surgery enables physicians to apply appropriate treatment plans and different follow-up strategies to improve patient survival. Overall, 30–50% of CRC patients experience cancer recurrence after radical surgery, but current surveillance tools have limitations in the precise and early detection of cancer recurrence. Circulating tumor cells (CTCs) are cancer cells that detach from the primary tumor and enter the bloodstream. These can provide real-time information on disease status. CTCs might become novel markers for predicting CRC recurrence and, more importantly, for making decisions about additional adjuvant chemotherapy. In this review, the clinical application of CTCs as a therapeutic marker for stage II CRC is described. It then discusses the utility of CTCs for monitoring cancer recurrence in advanced rectal cancer patients who undergo neoadjuvant chemoradiotherapy. Finally, it discusses the roles of CTC subtypes and CTCs combined with clinicopathological factors in establishing a multimarker model for predicting CRC recurrence.

show abstract

Section: Prevention and Detection Of Colorectal Cancer Recurrencementioning

confidence: 99%

Current Applications and Future Directions of Circulating Tumor Cells in Colorectal Cancer Recurrence

Tsai,

Huang,

Chu

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Firstly, MRD results could substantially contribute to personalized adjuvant treatment decisions. Patients traditionally categorized as stage I, and thus commonly excluded from chemotherapy regimens, have been observed to have a relapse rate of 2.3% to 4.7% within 5 years after curative resection [31,32]. MRD assessment might effectively identify high-risk patients who previously presented challenges to categorize, offering significant guidance in treatment selection and strategies.…”

Section: Personalized Treatment Choices: Can Mrd Inform Adjuvant Deci...mentioning

confidence: 99%

Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges

Wen,

Coradduzza,

Shen

et al. 2023

Medicina

View full text Add to dashboard Cite

Minimal Residual Disease (MRD) detection has emerged as an independent factor in clinical and pathological cancer assessment offering a highly effective method for predicting recurrence in colorectal cancer (CRC). The ongoing research initiatives such as the DYNAMIC and CIRCULATE-Japan studies, have revealed the potential of MRD detection based on circulating tumor DNA (ctDNA) to revolutionize management for CRC patients. MRD detection represents an opportunity for risk stratification, treatment guidance, and early relapse monitoring. Here we overviewed the evolving landscape of MRD technology and its promising applications through the most up-to-date research and reviews, underscoring the transformative potential of this approach. Our primary focus is to provide a point-to-point perspective and address key challenges relating to the adoption of ctDNA-based MRD detection in the clinical setting. By identifying critical areas of interest and hurdles surrounding clinical significance, detection criteria, and potential applications of basic research, this article offers insights into the advancements needed to evaluate the role of ctDNA in CRC MRD detection, contributing to favorable clinical options and improved outcomes in the management of CRC.

show abstract

Impact of Multidisciplinary Team Management on Survival and Recurrence in Stage I–III Colorectal Cancer: A Population-Based Study in Northern Italy

Mangone,

Zizzo,

Nardecchia

et al. 2024

Biology

View full text Add to dashboard Cite

This study aimed to assess whether multidisciplinary team (MDT) management improves outcomes in patients with stage I–III colorectal cancer (CRC) compared to non-MDT care. This study included 460 CRC patients diagnosed from 2017 to 2018 in a northern Italian province, of whom 300 (65%) were managed by MDT. MDT patients were younger, more frequently had rectal cancers, were diagnosed at earlier stages, and were more likely to undergo surgery and chemotherapy. Disease-free survival (DFS) and overall survival (OS) were significantly better in the MDT group. The recurrence rate was 8.5%, with no significant differences between MDT and non-MDT patients, although MDT patients exhibited lower recurrence rates for early-stage tumors. A multivariable analysis showed that DFS and OS were adversely affected by older age, advanced stage, and lack of MDT management. Kaplan–Meier estimates demonstrated a 3-year DFS of 78% in the MDT group versus 65% in the non-MDT group, as well as an OS of 83% versus 69%, respectively. The MDT approach was associated with improved treatment adherence and better management of recurrences. While limited by a small sample size, this population-based study highlights the beneficial impact of MDT care on CRC outcomes. Further research with extended follow-up is warranted to confirm these findings.

show abstract

Risk factors of recurrence in TNM stage I colorectal cancer

Cited by 8 publications

References 24 publications

Current Applications and Future Directions of Circulating Tumor Cells in Colorectal Cancer Recurrence

Current Applications and Future Directions of Circulating Tumor Cells in Colorectal Cancer Recurrence

Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges

Impact of Multidisciplinary Team Management on Survival and Recurrence in Stage I–III Colorectal Cancer: A Population-Based Study in Northern Italy

Contact Info

Product

Resources

About